NEW Danaher-IGI Beacon for CRISPR Cures center and their groundbreaking research into HLH! 

Last month it was announced that University of California Colleges: UCSF, UCLA and UC Berkeley, were teaming up with the Danaher Corporation and the Innovative Genomics Institute (IGI) to open the Danaher-IGI Beacon for CRISPR Cures center.
This center will work to create gene editing therapies to help those with rare diseases and familial hemophagocytic lymphohistiocytosis (fHLH) is one of the first two diseases they are focusing on.
In this video Deanna sits down with the head of the program, Dr. Fyodor Urnov, lead of the basic science behind this project, Dr. David Nguyen, and clinical lead, and a member of the Histiocyte Society, Dr. Michelle Hermiston MD.
We are so grateful that Danaher and IGI took up the cause of HLH and we are looking forward to the potential gene editing therapies in the upcoming years.
Stay tuned for future updates from this effort.